Next Article in Journal
High Monocyte Count Associated with Human Cytomegalovirus Replication In Vivo and Glucocorticoid Therapy May Be a Hallmark of Disease
Next Article in Special Issue
The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands
Previous Article in Journal
In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate against Toxoplasma gondii
 
 
Article
Peer-Review Record

Polymorphisms in the Genes Coding for TLRs, NLRs and RLRs Are Associated with Clinical Parameters of Patients with Acute Myeloid Leukemia

Int. J. Mol. Sci. 2022, 23(17), 9593; https://doi.org/10.3390/ijms23179593
by Katarzyna Wicherska-Pawłowska 1, Katarzyna Bogunia-Kubik 2, Bartłomiej Kuszczak 1, Piotr Łacina 2, Marta Dratwa 2, Bożena Jaźwiec 1, Tomasz Wróbel 1 and Justyna Rybka 1,*
Reviewer 1: Anonymous
Reviewer 2:
Int. J. Mol. Sci. 2022, 23(17), 9593; https://doi.org/10.3390/ijms23179593
Submission received: 14 July 2022 / Revised: 19 August 2022 / Accepted: 22 August 2022 / Published: 24 August 2022
(This article belongs to the Special Issue Advances in Therapy of Acute Myeloid Leukemia)

Round 1

Reviewer 1 Report

The authors have examined the potential impact of a series of SNPs associated with Toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) in Acute myeloid leukemia.  

It is by nature of examining SNPs that the numbers can be very repetitive and difficult for the reader to follow.  This is particularly evident in Section 2.1 where the clinical parameter is associated with each SNP; I wonder if might be more relevant for each SNP to associated with the clinical parameters or perhaps a summary table would be useful.   

Also many of the correlations are greater than 0.05 - although they do say tended to be associated - but without this virtually all correlations were not statistically significant.  

Figures 1 - 3 could be combined into one figure.   The increased rate of infections associated with some SNPs is interesting and have the authors considered looking at overall survival or risk group status for these patients.   Are they for example primary or secondary AML patients?

Overall, some interesting data that could be expanded in to a more clinically relevant study.

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Considering the high heterogeneity of AML between young and elderly (biology, responses, infections, outcomes, etc) it is relevant to distinguish the analysis according to the age (material methods, results and conclusion)

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors have addressed my previous comments

Back to TopTop